Eyevensys, a privately held, clinical-stage biotechnology company developing non-viral gene therapies for ophthalmic diseases, has entered into multi-year strategic agreements with US-based medical device manufacturers Phillips-Medisize and Minnetronix
Haag-Streit UK, a leading manufacturer and distributor of ophthalmic, optometry, and orhtopic equipment, has announced the launch of the MR Q Combo laser system in the UK.
In the light of growing prevalence of eye misalignment, Neurolens and Digital Vision, Inc. (DVI) have formed a collaboration to expand the prism field from 1/8th prism diopter to 1/100th prism diopter for all Neurolens designs.
Pharos Capital Group, a middle-market private equity firm based in Dallas and Nashville, has acquired Vantage Outsourcing, a leading cataract surgical service provider, in line with its mission to improve health care services in rural and underserved area
Aurion Biotech, a clinical-stage biotech company, has appointed Tim Largen as VP of manufacturing.
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, has entered into licensing agreement with Attillaps Holdings,
Visus Therapeutics Inc., a clinical-stage pharmaceutical company focused on developing innovative ophthalmic therapies to improve vision for people around the world, unveiled additional ophthalmic drug candidates (VT-201) with applications in development
Optimism Health Group, a healthcare investment business, has recently completed the acquisition of VisionCall, the UK's leading provider of eye care services in care homes. The acquisition came in line with Optimism’s plans to expand its footprint in the